Abstract. In the treatment of advanced or recurrent gastric cancer, the prolongation of survival depends on the use of second-line therapy, with paclitaxel (PTX) or irinotecan (CPT-11) as the key agents. The present study aimed to retrospectively investigate the safety and continuity of weekly PTX and CPT-11 monotherapy as second-or third-line treatment for advanced or recurrent gastric cancer. A total of 62 patients who had received PTX or CPT-11 for gastric cancer at the Ogaki Municipal Hospital (Ogaki, Japan) were retrospectively reviewed. Of the 47 patients who received PTX as second-line therapy, 13 (27.7%) received third-line therapy with CPT-11. Second-line PTX and third-line CPT-11 were discontinued due to progressive disease (PD) in 27 and 7 cases, respectively, and deterioration in the performance status (PS) in 20 and 4 cases, respectively. Only 1 case of discontinuation due to adverse events (AEs) was reported for third-line CPT-11. Furthermore, of the 15 patients who received CPT-11 as second-line treatment, 11 (73.3%) then received PTX as third-line treatment. Second-line CPT-11 and third-line PTX were discontinued due to PD in 9 and 6 cases, respectively, and deterioration in the PS in 4 and 5 cases, respectively, whereas there was only 1 case of discontinuation due to AEs for second-line CPT-11. Severe AEs for PTX and CPT-11 were infrequent; however, the frequency of diarrhea was high when PTX was administered as third-line therapy (63.6%), whereas the frequency of malaise was high when CPT-11 was administered as second-(73.3%) and third-line (76.9%) therapy. In conclusion, severe AEs due to PTX and CPT-11 as second-and third-line treatment for advanced or recurrent gastric cancer are infrequent and patients are generally able to continue treatment. However, the possibility of diarrhea with third-line PTX and malaise with second-and third-line CPT-11 treatment should be considered when planning chemotherapy.
Introduction
Tegafur-gimeracil-oteracil potassium (S-1) plus cisplatin is currently recommended as the standard first-line chemotherapy for advanced or recurrent gastric cancer in Japan, according to the results of the Japan Clinical Oncology Group 9912 (1) and those of the S-1 plus cisplatin vs. S-1 alone in randomized clinical trials for the first-line treatment of advanced gastric cancer (SPIRITS) trial (2) . As regards second-line treatment, weekly paclitaxel (PTX) (3) (4) (5) (6) (7) (8) (9) , irinotecan (CPT-11) monotherapy (10-15), S-1 plus PTX (16) and S-1 plus CPT-11 (17, 18) are used in daily practice. The prolongation of survival depends on the treatment following first-line therapy, with PTX and CPT-11 used as the key agents (19) (20) (21) .
Akasaka et al (22) reported that tolerability to S-1 plus CPT-11 for advanced or recurrent gastric cancer differs between cases with a performance status (PS) of 2 and those with a PS of 0-1. In addition, we previously reported a high frequency of adverse events (AEs) associated with S-1 plus cisplatin treatment or S-1 monotherapy in patients with a poor nutritional status (23, 24) and observed that a PS of ≥1 and serum albumin levels (Alb) of <3.5 g̸dl were risk factors for discontinuation of treatment due to AEs. Therefore, the tolerance to CPT-11 and PTX may decrease with deterioration of the patient's condition. In particular, we hypothesized that tolerance to chemotherapy decreases with the transition from second-to third-line therapy. However, the frequency of AEs and treatment continuity associated with second-and third-line chemotherapy with PTX or CPT-11 have not been sufficiently investigated. Therefore, this study aimed to retrospectively investigate the safety and continuity of PTX and CPT-11 as second-and third-line treatment for advanced or recurrent gastric cancer. Statistical analysis. The Mann-Whitney U test was used for comparisons between two groups and comparisons among multiple groups were performed with one-factor analysis of variance. In all significance tests, P<0.05 was considered to indicate a statistically significant difference.
Subjects and methods

Patients
Results
Patient characteristics.
The patient characteristics are summarized in Table I . For the patients who received second-line PTX and CPT-11, the median age was 65 years (range, 49-79 years) and 66 years (range, 42-78 years), respectively; unresectable tumors were identified in 35 and 4 cases and recurrent disease in 12 and 11 cases (P=0.0016), respectively. Peritoneal metastasis was identified in 26 and 2 patients who received second-line PTX and CPT-11, with a PS of 1 (range, 0-2) and 0 (range, 0-2), respectively. Furthermore, the patients who received second-line PTX and CPT-11 had an Alb level of 3.7 g̸dl (range, 2.0-4.5 g̸dl) and 4.1 g̸dl (range, 2.4-4.9 g̸dl), respectively.
Reasons for discontinuation and AEs with second-and third-line therapy in patients who received second-line PTX.
The reasons for treatment discontinuation and the AEs with second-and third-line treatment in patients who received second-line PTX are summarized in Tables II and III , respectively.
Rate of transition to third-line treatment. Of the 47 patients who received second-line PTX, 13 (27.7%) later received third-line treatment.
Reasons for discontinuation. Second-line PTX or third-line CPT-11 were discontinued due to progressive disease (PD) in 27 and 7 cases, respectively and deterioration in the PS in 20 and 4 cases, respectively. Discontinuation due to AEs was reported in only 1 case of third-line CPT-11. That patient requested withdrawal of the treatment due to nausea.
Duration of therapy and treatment dose. The duration of therapy was 120 days (range, 7-1,119 days) and 182 days (range, 28-497 days) and the median treatment dose was 100% (range, 60-100%) and 100% (range, 80-100%) for patients who received second-line PTX and third-line CPT-11, respectively.
PS and serum Alb level. Patients who received second-line PTX and then third-line treatment had a PS of 1 (range, 0-1) and 1 (range, 0-2) and Alb levels of 3.7 g̸dl (range, 3.1-4.3 g̸dl) and 3.5 g̸dl (range, 2.3-4.3 g̸dl), respectively, prior to the administration of second-and third-line treatment.
AEs. The AEs observed following second-line PTX included neutropenia (59.6%), leukopenia (59.6%), oligochromemia (76.6%), sensory neuropathy (76.6%) and constipation (68.1%). The AEs observed with third-line CPT-11 included malaise (76.9%) and oligochromemia (76.9%). Others ( 
Reasons for discontinuation and AEs with second-and third-line therapy in patients who received second-line CPT-11.
The reasons for discontinuation and the AEs associated with second-and third-line therapy in patients who received second-line CPT-11 are summarized in Tables IV and V, respectively.
Rate of transition to third-line treatment. Of the 15 patients who received second-line CPT-11, 11 (73.3%) then received third-line treatment.
Reasons for discontinuation. Second-line CPT-11 or third-line PTX was discontinued due to PD in 9 and 6 cases, respectively, and deterioration in the PS in 4 and 5 cases, respectively. Discontinuation due to AEs was reported in only 1 case following second-line CPT-11. That patient experienced anorexia and malaise.
Duration of therapy and treatment dose. The duration of therapy was 138 days (range, 28-566 days) and 110 days (range, 17-350 days) and the treatment dose was 100% (range, 80-100%) and 100% (range, 100-100%) for patients who received second-line CPT-11 and third-line PTX, respectively.
PS and serum Alb level. The patients who received second-line CPT-11 and then third-line treatment had a PS of 0 (range, 0-1) and 0 (range, 0-2) and Alb levels of 4.2 g̸dl (range, 3.2-4.9 g̸dl) and 4.1 g̸dl (range, 3.2-4.8 g̸dl), respectively, prior to second-and third-line treatment.
AEs. The AEs observed with second-line CPT-11 were mainly malaise (73.3%) and nausea (60.0%), whereas diarrhea (63.6%) and sensory neuropathy (63.6%) were commonly observed with third-line PTX (Table V) .
Incidence of neutropenia with second-and third-line treatment in patients who transitioned to third-line treatment.
A total of 15 patients experienced neutropenia with second-line treatment (PTX or CPT-11) and 5 patients experienced neutropenia with third-line treatment (PTX or CPT-11); the difference was found to be statistically significant (P=0.0039; Table VI ). 
Discussion
CPT-11 and PTX as second-and third-line chemotherapies are currently the most effective treatments for advanced or recurrent gastric cancer (19) ; however, the tolerability to treatment may be reduced, depending on the condition of the patients (22) (23) (24) . The findings of 4,007 comparative phase III trials of PTX and CPT-11 as second-line treatment for advanced gastric cancer, conducted by the West Japan Oncology Group (WJOG; WJOG4007) were reported at the American Society of Clinical Oncology meeting in 2012 (25) . Ueda et al (25) reported that the rate of transition from second-to third-line treatment was higher with second-line CPT-11 (90%) compared to that with second-line PTX (72%).
In our study, the patients who received second-line PTX exhibited a lower transition rate from second-to third-line treatment (27.7%). As regards PS and Alb levels prior to second-line treatment, the general condition of the patients who received second-line PTX was poor prior to second-line chemotherapy. PTX is often selected for patients with peritoneal dissemination, which was frequently the case in the present study. Therefore, we hypothesized that the transition from second-to third-line treatment may be difficult for patients who receive second-line PTX. However, in the WJOG4007 trials, patients with extensive peritoneal dissemination were excluded (25) . Accordingly, the difference in the rate of transition to third-line treatment between the present study and the WJOG4007 trials is likely be due to differences between the clinical trial setting and the actual clinical setting.
The discontinuation of second-and third-line treatment (Table II) were commonly due to PD and a decrease in the PS, whereas discontinuation due to AEs was observed in only 1 case. Additionally, the majority of treatment doses were 100% in the patients who received second-line PTX or third-line CPT-11 and the general condition of the patients who transitioned to third-line treatment was poor; however, in this study, the incidence of severe AEs was low. Accordingly, we considered second-line PTX and third-line CPT-11 to be tolerable and patients may successfully continue treatment in the actual clinical setting.
As regards AEs following second-line PTX and third-line CPT-11 in patients who received second-line PTX, the frequency of malaise was high (76.9%) with third-line CPT-11. Although malaise is not commonly considered to be a severe AE, it may be perceived as severe if the general condition of the patient is poor. For second-line PTX and third-line CPT-11, the frequency of oligochromemia was high (~77%); however, Table III . Adverse events with second-and third-line therapy in patients who received second-line PTX.
Second-line PTX a (n=47) Third-line CPT-11 b (n=13) ------------------------------------------------------------------------------------------------------------------------------------------------------Adverse events
All grades (%) Grade ≥3 (%) All grades (%) Grade ≥3 (%) this may be attributed to the waning nutritional status of pretreated patients.
In the patients who received second-line CPT-11, the rate of transition from second-to third-line treatment (73.3%) was comparable to that reported in the WJOG4007 study (Table IV) . Furthermore, in a previous study conducted by Kawamura et al (11) , it was reported that if the AEs are mild and the PS is good, third-line treatment is appropriate. In the present study, based on the Alb levels and the PS, the general condition of the patients who were unable to transition to third-line treatment was considered to be poor prior to second-line chemotherapy. In addition, during third-line CPT-11, the general condition of the patients was considered to have further deteriorated.
The majority of the treatment doses were 100% in the patients who received second-line CPT-11 or third-line PTX and severe AEs were infrequent with second-line CPT-11 and third-line PTX, whereas discontinuation due to AEs was reported in only 1 case. A previous study by Farhat (15) reported that hematological and digestive toxicities were tolerable and mild with irinotecan-based chemotherapy, particularly with a weekly regimen. Therefore, CPT-11 as second-line and PTX as third-line treatment are considered to be tolerable and patients may successfully continue treatment in the clinical setting.
As regards AEs following second-line CPT-11 and third-line PTX in patients who received second-line CPT-11, the frequency of malaise was found to be high (73.3%) with second-line CPT-11, similar to that for third-line CPT-11 in patients who received second-line PTX. The frequency of diarrhea with PTX was higher in the third-line (63.6%) compared to that in the second-line setting (8.5%), possibly due to disease progression.
In the patients who received PTX or CPT-11 as second-line treatment and transitioned to third-line treatment, neutropenia was more frequently observed during second-line compared to that during third-line treatment; these patients were not administered a reduced dose during third-line treatment. A previous study by Shitara et al (26) reported a correlation between prognosis and the occurrence of neutropenia in patients receiving PTX as second-line treatment. Similarly, there may exist a correlation between prognosis and neutropenia for third-line treatment; therefore, we consider this to be an important focus of future investigations.
In conclusion, second-or third-line treatment with PTX or CPT-11 for patients with advanced or recurrent gastric cancer has been associated with a low incidence of severe AEs and the patients were able to successfully continue treatment. However, the incidence of diarrhea during treatment with PTX in the third-line setting and that of malaise during treatment with CPT-11 in the second-and third-line setting must be carefully considered when planning chemotherapy for such patients. Table V . Adverse events with second-and third-line therapy in patients who received second-line CPT-11. 
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